Beam Therapeutics Inc.
BEAMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. With a market capitalization of $2.48B, it sits in mid-cap territory. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Market Cap
$2.48B
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
-5.11
EPS (TTM)
$-0.68
EPS (Fwd)
$-4.70
ROE
-8.2%
ROA
-17.0%
Cash
$1.15B
Total Debt
$247.4M
Free CF
-$241.8M
52W Change
-10.0%
Annual Financials
Cash vs Debt
Where BEAM stands vs its 150-day and 200-day moving averages
As of the October 2, 2026 close, BEAM finished 14.18% below its 150-day moving average ($28.42) and 14.39% below its 200-day moving average ($28.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BEAM overbought or oversold?
At the October 2, 2026 close, BEAM's RSI(14) was 53.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.15B in cash and $247.4M in debt, BEAM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$241.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -8.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $60.9M (2022) to $139.7M (2025), reflecting a 129% increase over the period.
Beam Therapeutics Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, BEAM has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BEAM.